Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.

Conclusions. No strong conclusions can be drawn regarding the role of lifestyle-related factors in the management of CIPN in CRC patients. Certain dietary supplements and physical exercise may be beneficial for the management of CIPN, but further research is warranted. PMID: 28400846 [PubMed - in process]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Related Links:

Conclusion: Our study lays ground for further larger scale longitudinal studies on oxaliplatin neurotoxicity and its prevention. We believe that early diagnosis of oxaliplatin-induced neurotoxicity is essential in the prevention of irreversible nerve damage and should be prioritized when assessing and evaluating treatment so that adequate adjustment may be made.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Chemotherapy-induced Peripheral Neuropathy Interventions:   Drug: Calmangafodipir (2 µmol/kg);   Drug: Calmangafodipir (5 µmol/kg);   Drug: Placebo Sponsor:   PledPharma AB Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract BACKGROUND: Oxaliplatin (OXA) is a cornerstone in the treatment of colorectal cancer (CRC). Retreatment with OXA is frequently considered as salvage treatment. OXA-induced neuropathy (OIN) is the most frequent and feared long-term side effect. PATIENTS AND METHODS: CRC patients receiving at least twice OXA-based chemotherapy lines at our institution between June 2000 and July 2016 were reviewed. The aim of this study was to investigate whether retreatment with OXA increases the risk of developing new or worsening previous neuropathy. OIN was assessed by National Cancer Institute-Common Toxicity Crite...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
AbstractBackgroundOxaliplatin (OXA) is a cornerstone in the treatment of colorectal cancer (CRC). Retreatment with OXA is frequently considered as salvage treatment. OXA-induced neuropathy (OIN) is the most frequent and feared long-term side effect.Patients and methodsCRC patients receiving at least twice OXA-based chemotherapy lines at our institution between June 2000 and July 2016 were reviewed. The aim of this study was to investigate whether retreatment with OXA increases the risk of developing new or worsening previous neuropathy. OIN was assessed by National Cancer Institute-Common Toxicity Criteria for Adverse Even...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 15 August 2018Source: Life Sciences, Volume 207Author(s): Kentaro Nishida, Kazuya Takeuchi, Ayami Hosoda, Shohei Sugano, Eri Morisaki, Akihiro Ohishi, Kazuki NagasawaAbstractAimsOxaliplatin (l-OHP) is a key drug in therapeutic regimens for metastatic or advanced-stage colorectal cancer, but causes peripheral neuropathy as a dose-limiting adverse effect. It is reported that this peripheral neuropathy results from l-OHP accumulation in dorsal root ganglion (DRG) neurons, and that one of the transporters responsible for the accumulation in DRG neurons is organic cation transporter novel (OCTN) 1. Here, we ex...
Source: Life Sciences - Category: Biology Source Type: research
Introduction: mFOLFOX6 is a common first-line chemotherapy regimen for patients with unresectable, advanced or recurrent colorectal cancer (CRC). However, the long-term administration of oxaliplatin is associated with peripheral neuropathy (PN). Recently, we reported that 5-fluorouracil (5-FU)/leucovorin (LV) + panitumumab therapy after 6 fixed cycles of mFOLFOX6 + panitumumab therapy maintained efficacy with reduced incidence of PN, compared with continued treatment with mFOLFOX6 + panitumumab. Here, we report results from the final analysis of efficacy and safety endpoints (data cut-off: 31 Aug 2017), and from subgroup a...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Introduction: Oxaliplatin (OXA) is a cornerstone in the treatment of colorectal cancer (CRC). Retreatment with OXA is frequently considered as salvage treatment. OXA-induced neuropathy (OIN) is the most frequent and feared long-term side-effect.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Acupuncture | Alternative and Complementary Therapies | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Complementary Medicine | Eloxatin | Herbs | Neurology | Nutrition | Peripheral Neuropathy | Sports Medicine | Study